Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06921785 · ClinicalTrials.gov registry record · Phase 3

Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma

A Phase 3 study of Hepatocellular Carcinoma, sponsored by AstraZeneca.

Recruiting
Registry status
Phase 3
Development phase
1,220
Enrollment target
20
Study locations

NCT06921785 is a Phase 3 study of Hepatocellular Carcinoma that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 1,220 participants, above the 249-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (390% higher). The trial reports 20 study locations across 14 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06921785, a Phase 3 study of Hepatocellular Carcinoma, is actively recruiting participants, sponsored by AstraZeneca.

RECRUITING
Registry status
Phase 3
Development phase
1,220 participants
Enrollment target
20
Study locations

Study Summary

This is a Phase III, randomised, open-label, sponsor-blinded, 3-arm, multicentre, global study assessing the efficacy and safety of rilvegostomig in combination with bevacizumab with or without tremelimumab compared to atezolizumab in combination with bevacizumab. This study will be conducted in participants with advanced HCC who are not amenable to curative therapy or locoregional therapy

Conditions Studied

Hepatocellular Carcinoma

Interventions

  • DRUG Bevacizumab
  • DRUG Atezolizumab
  • DRUG Rilvegostomig
  • DRUG Tremelimumab

Study Locations (20)

New York

  • Research Site - New York
  • Research Site - New York
  • Research Site - New York

Arizona

  • Research Site - Phoenix
  • Research Site - Tucson

California

  • Research Site - Palo Alto
  • Research Site - Santa Monica

Georgia

  • Research Site - Atlanta
  • Research Site - Fayetteville

Michigan

  • Research Site - Detroit
  • Research Site - Grand Rapids

Connecticut

  • Research Site - New Haven

Delaware

  • Research Site - Newark

Florida

  • Research Site - Jacksonville

Trial Details

FieldValue
Enrollment Target 1,220 participants
Start Date 2025-05-06
Est. Completion 2030-03-14
Phase Phase 3

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06921785

The ClinicalTrials.gov registry entry for NCT06921785 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 1,220 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 249-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (390% higher). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Hepatocellular Carcinoma appearing as the primary indexed condition, and to 4 interventions - of which Bevacizumab is the first listed.

NCT06921785 reports 20 study locations spanning 14 distinct geographic areas - top geographies include New York, Arizona, California.

Frequently Asked Questions

What is clinical trial NCT06921785 about?

NCT06921785 is a clinical study titled "Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma". This is a Phase III, randomised, open-label, sponsor-blinded, 3-arm, multicentre, global study assessing the efficacy and safety of rilvegostomig in combination with bevacizumab with or without tremelimumab compared to atezolizumab in combination with bevacizumab. This study will be conducted in par...

What is the current status of trial NCT06921785?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 1,220 participants. The study started on 2025-05-06. Estimated completion is 2030-03-14.

What conditions does trial NCT06921785 study?

This clinical trial studies the following conditions: Hepatocellular Carcinoma.

What interventions are being tested in trial NCT06921785?

The interventions under investigation include: Bevacizumab (DRUG), Atezolizumab (DRUG), Rilvegostomig (DRUG), Tremelimumab (DRUG).

Who is sponsoring clinical trial NCT06921785?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06921785 being conducted?

This trial has 20 study locations across Arizona, California, Connecticut, Delaware, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Hepatocellular Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Hepatocellular Carcinoma

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.